stoxline Quote Chart Rank Option Currency Glossary
  
Chemomab Therapeutics Ltd. (CMMB)
1.235  0.075 (6.47%)    07-23 16:00
Open: 1.165
High: 1.25
Volume: 62,690
  
Pre. Close: 1.16
Low: 1.15
Market Cap: 18(M)
Technical analysis
2024-07-23 4:51:15 PM
Short term     
Mid term     
Targets 6-month :  1.46 1-year :  1.7
Resists First :  1.25 Second :  1.46
Pivot price 1.08
Supports First :  0.95 Second :  0.77
MAs MA(5) :  1.16 MA(20) :  1.05
MA(100) :  0.87 MA(250) :  0.81
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  77.3 D(3) :  71
RSI RSI(14): 64.8
52-week High :  1.37 Low :  0.41
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CMMB ] has closed below upper band by 5.0%. Bollinger Bands are 19.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.25 - 1.26 1.26 - 1.26
Low: 1.14 - 1.14 1.14 - 1.15
Close: 1.23 - 1.23 1.23 - 1.24
Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Headline News

Sat, 20 Jul 2024
Chemomab Therapeutics (NASDAQ:CMMB) Shares Down 0.9% - American Banking and Market News

Wed, 08 May 2024
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Yahoo Finance

Tue, 20 Feb 2024
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases - PR Newswire

Wed, 14 Feb 2024
symbol__ Stock Quote Price and Forecast - CNN

Wed, 15 Nov 2023
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis - PR Newswire

Mon, 06 Nov 2023
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 14 (M)
Shares Float 188 (M)
Held by Insiders 14.9 (%)
Held by Institutions 23.8 (%)
Shares Short 100 (K)
Shares Short P.Month 62 (K)
Stock Financials
EPS -1.54
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.93
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -48.3 %
Return on Equity (ttm) -93.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.44
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.81
PEG Ratio 0
Price to Book value 1.31
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android